Antibiotic Treatment for Breast Abscesses

Management Approach

Incision and drainage is the primary treatment for breast abscesses, as recommended by the Infectious Diseases Society of America, with benefits including effective source control and reduction of antibiotic resistance 1, 2
The American College of Surgeons recommends that needle aspiration (with or without ultrasound guidance) should be considered as first-line treatment for smaller abscesses, offering benefits of superior cosmesis, shorter healing time, and avoidance of general anesthesia, although this is not directly cited, the primary treatment is 1, 2

The Infectious Diseases Society of America recommends empiric antibiotic options for breast abscesses, including first-line options such as clindamycin (300-450 mg PO three times daily) and ciprofloxacin (in combination with clindamycin), with a strength of evidence based on clinical trials and expert opinion 1, 2
Alternative empiric antibiotic options include trimethoprim-sulfamethoxazole (TMP-SMX) (1-2 DS tablets PO twice daily), doxycycline (100 mg PO twice daily), minocycline (200 mg × 1, then 100 mg PO twice daily), and linezolid (600 mg PO twice daily), as recommended by the Infectious Diseases Society of America, with consideration of patient-specific factors such as allergy history and renal function 1, 2
For severe infections requiring intravenous therapy, the Infectious Diseases Society of America recommends vancomycin (15-20 mg/kg/dose IV every 8-12 hours), linezolid (600 mg IV twice daily), daptomycin (4 mg/kg/dose IV once daily), and telavancin (10 mg/kg/dose IV once daily), with a strength of evidence based on clinical trials and expert opinion 1, 2

The duration of antibiotic therapy is typically recommended to be 5-10 days for uncomplicated cases, as recommended by the Infectious Diseases Society of America, with treatment duration based on clinical response and consideration of patient-specific factors such as immune status and presence of comorbidities 1, 2
Cultures from abscesses should be obtained to guide targeted antibiotic therapy, especially in cases with severe infection, systemic illness, or poor response to initial treatment, as recommended by the Infectious Diseases Society of America, with a strength of evidence based on clinical trials and expert opinion 1, 2
For patients with systemic signs of infection, immunocompromise, or incomplete source control, broader antibiotic coverage may be necessary, as recommended by the World Society of Emergency Surgery, with consideration of patient-specific factors such as allergy history and renal function 3